Trial Profile

A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Oct 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tanruprubart (Primary) ; Immunoglobulins
Indications Guillain-Barre syndrome
Focus Adverse reactions
Sponsors Annexon

Most Recent Events

10 Oct 2023 According to an Annexon media release, company announced that the European Medicines Agency (EMA) granted orphan drug designation to ANX005 for the treatment of Guillain-Barre Syndrome (GBS).
26 Apr 2022 Results presented at the 74th Annual Meeting of the American Academy of Neurology 2022
16 Aug 2021 According to an Annexon media release, data from this study presented at the 2021 Peripheral Nerve Society Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com